Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/42937
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorGaleano Jaramillo, Elkin de Jesús-
dc.contributor.authorVelásquez Bedoya, Paula Andrea-
dc.contributor.authorHernández López, Juan Carlos-
dc.contributor.authorHincapié García, Jaime Alejandro-
dc.contributor.authorRugeles López, María Teresa-
dc.contributor.authorZapata Builes, Wildeman-
dc.date.accessioned2024-10-29T01:13:03Z-
dc.date.available2024-10-29T01:13:03Z-
dc.date.issued2024-
dc.identifier.citationVelásquez PA, Hernandez JC, Galeano E, Hincapié-García J, Rugeles MT, Zapata-Builes W. Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review. Clin Pharmacol. 2024 Jan 4;16:1-25. doi: 10.2147/CPAA.S429064.spa
dc.identifier.urihttps://hdl.handle.net/10495/42937-
dc.description.abstractABSTRACT: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a betacoronavirus responsible for the COVID-19 pandemic, causing respiratory disorders, and even death in some individuals, if not appropriately treated in time. To face the pandemic, preventive measures have been taken against contagions and the application of vaccines to prevent severe disease and death cases. For the COVID-19 treatment, antiviral, antiparasitic, anticoagulant and other drugs have been reused due to limited specific medicaments for the disease. Drug repurposing is an emerging strategy with therapies that have already tested safe in humans. One promising alternative for systematic experimental screening of a vast pool of compounds is computational drug repurposing (in silico assay). Using these tools, new uses for approved drugs such as chloroquine, hydroxychloroquine, ivermectin, zidovudine, ribavirin, lamivudine, remdesivir, lopinavir and tenofovir/emtricitabine have been conducted, showing effectiveness in vitro and in silico against SARS-CoV-2 and some of these, also in clinical trials. Additionally, therapeutic options have been sought in natural products (terpenoids, alkaloids, saponins and phenolics) with promising in vitro and in silico results for use in COVID-19 disease. Among these, the most studied are resveratrol, quercetin, hesperidin, curcumin, myricetin and betulinic acid, which were proposed as SARSCoV-2 inhibitors. Among the drugs reused to control the SARS-CoV2, better results have been observed for remdesivir in hospitalized patients and outpatients. Regarding natural products, resveratrol, curcumin, and quercetin have demonstrated in vitro antiviral activity against SARS-CoV-2 and in vivo, a nebulized formulation has demonstrated to alleviate the respiratory symptoms of COVID-19. This review shows the evidence of drug repurposing efficacy and the potential use of natural products as a treatment for COVID-19. For this, a search was carried out in PubMed, SciELO and ScienceDirect databases for articles about drugs approved or under study and natural compounds recognized for their antiviral activity against SARS-CoV-2.spa
dc.format.extent25 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherDove Pressspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/2.5/co/*
dc.titleEffectiveness of drug repurposing and natural products against SARS-CoV-2: A comprehensive reviewspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupInmunovirologíaspa
dc.publisher.groupProductos Naturales Marinosspa
dc.publisher.groupPromoción y Prevención Farmacéuticaspa
dc.identifier.doi10.2147/CPAA.S429064-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1179-1438-
oaire.citationtitleClinical Pharmacology: Advances and Applicationsspa
oaire.citationstartpage1spa
oaire.citationendpage25spa
oaire.citationvolume16spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by-nc/4.0/spa
oaire.fundernameUniversidad de Antioquia. Vicerrectoría de investigación. Comité para el Desarrollo de la Investigación - CODIspa
oaire.fundernameUniversidad Cooperativa de Colombia. Comité para el Desarrollo de la Investigación CONADIspa
dc.publisher.placeAuckland, Nueva Zelandaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTREVspa
dc.type.localArtículo de revisiónspa
dc.subject.decsCOVID-19-
dc.subject.decsPandemias-
dc.subject.decsPandemics-
dc.subject.decsCoronavirus-
dc.subject.decsPlantas Medicinales-
dc.subject.decsPlants, Medicinal-
dc.subject.decsSARS-CoV-2-
dc.description.researchgroupidCOL0015043spa
dc.description.researchgroupidCOL0012444spa
dc.description.researchgroupidCOL0074661spa
oaire.awardnumberINV3159spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000086382-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D058873-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D017934-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D010946-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000086402-
dc.relation.ispartofjournalabbrevClin. Pharmacol.spa
oaire.funderidentifier.rorRoR:03bp5hc83-
oaire.funderidentifier.rorRoR:04td15k45-
Aparece en las colecciones: Artículos de Revista en Farmacéutica y Alimentarias

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
GaleanoElkin_2024_Effectiveness_Drug_Repurposing.pdfArtículo de revisión7.22 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons